RU2019130010A - Способы и композиции для лечения рака с помощью антисмысла - Google Patents
Способы и композиции для лечения рака с помощью антисмысла Download PDFInfo
- Publication number
- RU2019130010A RU2019130010A RU2019130010A RU2019130010A RU2019130010A RU 2019130010 A RU2019130010 A RU 2019130010A RU 2019130010 A RU2019130010 A RU 2019130010A RU 2019130010 A RU2019130010 A RU 2019130010A RU 2019130010 A RU2019130010 A RU 2019130010A
- Authority
- RU
- Russia
- Prior art keywords
- chamber
- tumor cells
- odn
- biodiffusion
- igf
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 230000000692 anti-sense effect Effects 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 claims 13
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 12
- 210000001519 tissue Anatomy 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 6
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 230000001464 adherent effect Effects 0.000 claims 3
- 102000004584 Somatomedin Receptors Human genes 0.000 claims 2
- 108010017622 Somatomedin Receptors Proteins 0.000 claims 2
- 238000005538 encapsulation Methods 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 102000008730 Nestin Human genes 0.000 claims 1
- 108010088225 Nestin Proteins 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 210000005055 nestin Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Claims (30)
1. Способ вакцинации субъекта с раком головного мозга, включающий
(i) получение жизнеспособной измельченной опухолевой ткани от субъекта;
(ii) сбор измельченной ткани в стерильном уловителе;
(iii) сбор адгезивных клеток из измельченной ткани;
(iv) инкапсуляцию собранных клеток в биодиффузионную камеру вместе с антисмысловым олигодезоксинуклеотидом рецептора инсулиноподобного фактора роста 1 (IGF-1R AS ODN), имеющим последовательность SEQ ID NO: 1;
(v) облучение камеры, и
(vi) имплантацию камеры субъекту, при этом получают иммунный ответ против рака головного мозга.
2. Способ по п. 1, включающий этап обработки адгезивных клеток посредством IGF-1R AS ODN в течение до 18 часов перед инкапсуляцией.
3. Способ по п. 1, в котором субъекта вакцинируют 20 камерами примерно на 48 часов.
4. Способ по п. 1, в котором камера содержит от примерно 1×104 до примерно 5×106 опухолевых клеток.
5. Способ по п. 4, в котором камера содержит от примерно 1×105 до примерно 1,5×106 опухолевых клеток.
6. Способ по п. 5, в котором камера содержит примерно 106 опухолевых клеток.
7. Способ по п. 1, в котором камера содержит от примерно 1 мкг до примерно 5 мкг IGF-1R AS ODN.
8. Способ п. 6, в котором камера содержит примерно 4 мкг IGF-1R AS ODN.
9. Способ по п. 1, в котором опухолевые клетки не подвергают воздействию температур выше температуры тела.
10. Способ по п. 1, в котором рак головного мозга выбран из астроцитомы стадии II, астроцитомы стадии AIII, астроцитомы стадии AIII-G и астроцитомы стадии IV (мультиформной глиобластомы).
11. Биодиффузионная камера для имплантации субъекту с раком головного мозга, содержащая
(a) облученные опухолевые клетки, при этом опухолевые клетки содержат адгезивные клетки, полученные из опухолевой ткани субъекта с помощью тканевого морцеллятора; и
(b) облученный IGF-1R AS ODN, причем IGF-1R AS ODN имеет последовательность SEQ ID NO:1.
12. Биодиффузионная камера по п. 11, в которой опухолевые клетки предварительно инкубированы с антисмысловым олигодезоксинуклеотидом рецептора инсулиноподобного фактора роста 1 (IGF-1R AS ODN) перед инкапсуляцией внутрь камеры.
13. Биодиффузионная камера по п. 11, при этом камера содержит от примерно 1 мкг до примерно 5 мкг IGF-1R AS ODN.
14. Биодиффузионная камера по п. 13, при этом камера содержит примерно 4 мкг IGF-1R AS ODN.
15. Биодиффузионная камера по п. 11, при этом опухолевые клетки в камере обогащены нестин-положительными клетками по сравнению с опухолевой тканью, полученной от субъекта.
16. Биодиффузионная камера по п. 11, в которой тканевый морцеллятор содержит высокоскоростную возвратно-поступательную внутреннюю канюлю внутри неподвижной внешней канюли.
17. Биодиффузионная камера по п. 11, в которой тканевый морцеллятор не вырабатывает тепло, направленное на ткань, при получении ткани от субъекта.
18. Биодиффузионная камера по п. 11, при этом камера содержит от примерно 1×104 до примерно 5×106 опухолевых клеток.
19. Биодиффузионная камера по п. 18, при этом камера содержит от примерно 1×105 до примерно 1,5×106 опухолевых клеток.
20. Биодиффузионная камера по п. 19, при этом камера содержит примерно 106 опухолевых клеток.
21. Биодиффузионная камера по п. 11, при этом отношение опухолевых клеток к AS ODN в камере составляет примерно 5,0×105 клеток: 1 мкг.
22. Биодиффузионная камера по п. 16, в которой внешняя канюля содержит боковое отверстие, при этом опухолевые клетки затягиваются в боковое отверстие электронно-управляемым изменяемым всасыванием.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762469003P | 2017-03-09 | 2017-03-09 | |
US62/469,003 | 2017-03-09 | ||
US201862629972P | 2018-02-13 | 2018-02-13 | |
US62/629,972 | 2018-02-13 | ||
PCT/US2018/021706 WO2018165528A1 (en) | 2017-03-09 | 2018-03-09 | Methods and compositions for treating cancers using antisense |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019130010A true RU2019130010A (ru) | 2021-04-10 |
RU2019130010A3 RU2019130010A3 (ru) | 2021-07-05 |
RU2766457C2 RU2766457C2 (ru) | 2022-03-15 |
Family
ID=62838976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019130010A RU2766457C2 (ru) | 2017-03-09 | 2018-03-09 | Способы и композиции для лечения рака с помощью антисмысла |
Country Status (13)
Country | Link |
---|---|
US (5) | US10357509B2 (ru) |
EP (1) | EP3592841B1 (ru) |
JP (2) | JP2020510021A (ru) |
KR (1) | KR20190140440A (ru) |
CN (1) | CN110832068A (ru) |
AU (1) | AU2018230458A1 (ru) |
BR (1) | BR112019018555A2 (ru) |
CA (1) | CA3054662A1 (ru) |
MX (1) | MX2019010725A (ru) |
NZ (1) | NZ756820A (ru) |
RU (1) | RU2766457C2 (ru) |
SG (2) | SG10202109912XA (ru) |
WO (1) | WO2018165528A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6957035B2 (ja) | 2015-04-10 | 2021-11-02 | トーマス・ジェファーソン・ユニバーシティ | 対象への移植用の免疫原性拡散チャンバおよびその調製方法 |
WO2018165528A1 (en) | 2017-03-09 | 2018-09-13 | Thomas Jefferson University | Methods and compositions for treating cancers using antisense |
MX2020007844A (es) * | 2018-01-24 | 2021-01-20 | Univ Jefferson | Camara de biodifusion. |
AU2019347999A1 (en) * | 2018-09-26 | 2021-04-22 | Thomas Jefferson University | Neoantigen compositions; and methods of preparation and use thereof |
AU2019374061A1 (en) * | 2018-11-02 | 2021-06-03 | Thomas Jefferson University | Methods and compositions for treating hepatocellular carcinoma using antisense |
MX2021005168A (es) * | 2018-11-02 | 2021-08-24 | Univ Jefferson | Metodos y composiciones para el tratamiento de cancer de mama usando antisentido. |
CA3134969A1 (en) * | 2019-03-28 | 2020-10-01 | Thomas Jefferson University | Methods for treating cancers using antisense |
WO2024077130A1 (en) * | 2022-10-05 | 2024-04-11 | Thomas Jefferson University | Methods and compositions for treating bladder cancer |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
JPH08508405A (ja) | 1993-03-26 | 1996-09-10 | トーマス ジェファーソン ユニバーシティ | Igf−1レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法 |
US5714170A (en) | 1994-11-16 | 1998-02-03 | Thomas Jefferson University | Method of inducing resistance to tumor growth |
US6541036B1 (en) * | 1997-05-29 | 2003-04-01 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR) |
AU5479899A (en) * | 1998-08-13 | 2000-03-06 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor |
US6144553A (en) | 1998-09-09 | 2000-11-07 | Sun Microsystems, Inc. | Refrigeration cooled disk storage assembly |
US7037335B2 (en) | 2002-11-19 | 2006-05-02 | Eagle Vision, Inc. | Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma |
JP4753863B2 (ja) | 2003-02-11 | 2011-08-24 | アンチセンス セラピューティクス リミテッド | インスリン様増殖因子i受容体発現の調節 |
US7846906B2 (en) | 2003-02-28 | 2010-12-07 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
CA2447400A1 (en) | 2003-09-12 | 2005-03-12 | The Hospital For Sick Children | Brain tumor stem cells |
US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
DK2633052T3 (en) * | 2010-10-27 | 2018-07-16 | Curna Inc | TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1 |
MX2016003615A (es) | 2013-09-24 | 2016-10-26 | Giner Inc | Sistema para tratamiento con gas de un implante de celulas. |
US9872674B2 (en) | 2014-05-07 | 2018-01-23 | Boehringer Laboratories Inc. | Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure |
JP6957035B2 (ja) | 2015-04-10 | 2021-11-02 | トーマス・ジェファーソン・ユニバーシティ | 対象への移植用の免疫原性拡散チャンバおよびその調製方法 |
WO2016172679A1 (en) * | 2015-04-23 | 2016-10-27 | Applied Medical Resources Corporation | Systems and methods for tissue removal |
US9744187B2 (en) | 2015-10-14 | 2017-08-29 | Bio-Path Holdings, Inc. | p-Ethoxy nucleic acids for liposomal formulation |
WO2018165528A1 (en) | 2017-03-09 | 2018-09-13 | Thomas Jefferson University | Methods and compositions for treating cancers using antisense |
MX2020007844A (es) * | 2018-01-24 | 2021-01-20 | Univ Jefferson | Camara de biodifusion. |
-
2018
- 2018-03-09 WO PCT/US2018/021706 patent/WO2018165528A1/en active Application Filing
- 2018-03-09 NZ NZ756820A patent/NZ756820A/en unknown
- 2018-03-09 AU AU2018230458A patent/AU2018230458A1/en active Pending
- 2018-03-09 CN CN201880018150.1A patent/CN110832068A/zh active Pending
- 2018-03-09 RU RU2019130010A patent/RU2766457C2/ru active
- 2018-03-09 SG SG10202109912X patent/SG10202109912XA/en unknown
- 2018-03-09 JP JP2019548594A patent/JP2020510021A/ja active Pending
- 2018-03-09 BR BR112019018555A patent/BR112019018555A2/pt unknown
- 2018-03-09 US US15/917,050 patent/US10357509B2/en active Active
- 2018-03-09 KR KR1020197029676A patent/KR20190140440A/ko not_active Application Discontinuation
- 2018-03-09 CA CA3054662A patent/CA3054662A1/en active Pending
- 2018-03-09 US US15/916,953 patent/US20180256625A1/en not_active Abandoned
- 2018-03-09 EP EP18764973.6A patent/EP3592841B1/en active Active
- 2018-03-09 MX MX2019010725A patent/MX2019010725A/es unknown
- 2018-03-09 SG SG11201908054XA patent/SG11201908054XA/en unknown
-
2019
- 2019-07-22 US US16/518,253 patent/US10772904B2/en active Active
-
2020
- 2020-09-15 US US17/020,879 patent/US11801259B2/en active Active
-
2023
- 2023-03-01 JP JP2023030687A patent/JP2023081916A/ja active Pending
- 2023-09-21 US US18/471,355 patent/US20240100078A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ756820A (en) | 2022-08-26 |
JP2023081916A (ja) | 2023-06-13 |
SG10202109912XA (en) | 2021-10-28 |
EP3592841A1 (en) | 2020-01-15 |
RU2766457C2 (ru) | 2022-03-15 |
MX2019010725A (es) | 2020-02-10 |
US20210060055A1 (en) | 2021-03-04 |
US20190365794A1 (en) | 2019-12-05 |
CN110832068A (zh) | 2020-02-21 |
US10772904B2 (en) | 2020-09-15 |
BR112019018555A2 (pt) | 2020-04-14 |
US11801259B2 (en) | 2023-10-31 |
KR20190140440A (ko) | 2019-12-19 |
US20240100078A1 (en) | 2024-03-28 |
EP3592841B1 (en) | 2024-02-14 |
US10357509B2 (en) | 2019-07-23 |
AU2018230458A1 (en) | 2019-09-05 |
JP2020510021A (ja) | 2020-04-02 |
US20180256625A1 (en) | 2018-09-13 |
US20180201939A1 (en) | 2018-07-19 |
SG11201908054XA (en) | 2019-09-27 |
CA3054662A1 (en) | 2018-09-13 |
WO2018165528A1 (en) | 2018-09-13 |
EP3592841A4 (en) | 2021-01-06 |
RU2019130010A3 (ru) | 2021-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019130010A (ru) | Способы и композиции для лечения рака с помощью антисмысла | |
WO2011140497A3 (en) | Method and apparatus for tissue grafting and copying | |
KR101163594B1 (ko) | 치아 골 이식재 제조방법 및 그로 인해 제조된 골 이식재 | |
CN104221672B (zh) | 一种韭黄的培育方法 | |
CN102577965B (zh) | 东方百合种球脱毒方法 | |
CN102487626A (zh) | 人参种子的物理处理方法 | |
CN105557514B (zh) | 一种金线莲种质资源的低温保存方法 | |
US20210370057A1 (en) | Methods for producing cardiomyocyte cells | |
JP5877565B2 (ja) | ツルレイシ属植物の栽培方法及びその乾燥粉末 | |
CN104604689A (zh) | 快速获得菊苣外植体和提高其出愈率的方法 | |
CN103907534B (zh) | 植物组织培养时的新类型外植体及其灭菌方法 | |
CN104689372A (zh) | 一种同种骨超临界二氧化碳脱脂处理的方法 | |
CN109793768A (zh) | 一种提高淫羊藿苷含量的药材加工处理方法 | |
CN109044421A (zh) | 一种四维极速种植头发的设备 | |
CN109517785B (zh) | 一种母鹿生茸区骨膜组织刺激生茸方法 | |
RU2646094C1 (ru) | Способ стимулирования корнеобразовательной способности черенков винограда | |
CN107771675A (zh) | 一种罗汉果种植方法 | |
CN106386060A (zh) | 一种亳菊的大规模种植方法 | |
RU2008117777A (ru) | Способ стимулирования роста и развития масличных культур | |
KR20120034922A (ko) | 대나무의 관상용 분화재배 및 제조방법 | |
TW202014092A (zh) | 誘導植物增加其黃酮類化合物之含量的方法 | |
CN215736092U (zh) | 一种棉花种植用土传病害处理装置 | |
KR101321877B1 (ko) | 항암유효성분이 함유된 마늘농축오일의 추출방법 | |
MX2021005168A (es) | Metodos y composiciones para el tratamiento de cancer de mama usando antisentido. | |
RU2626722C2 (ru) | Способ и устройство для борьбы с botrytis cinerea при выращивании привитых саженцев винограда |